Study of Temzolomide and Gleevec in Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00667953
Recruitment Status : Active, not recruiting
First Posted : April 28, 2008
Last Update Posted : September 26, 2016
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : March 2011
  Study Completion Date : No date given